US Patent 8,951,969: Scope, Claims, and Patent Landscape Analysis
Overview and Summary
US Patent 8,951,969, granted on February 10, 2015, covers a novel class of compounds and their pharmaceutical applications. The patent claims specific chemical structures, methods of synthesis, and therapeutic uses, particularly targeting diseases involving kinase activity modulation. Its patent scope aligns with a broader effort to secure proprietary rights for kinase inhibitors, especially those related to oncological treatments.
Patent Scope and Claims
Core Inventions
The patent claims cover:
- Chemical compounds: A defined class of heterocyclic kinase inhibitors, characterized by specific substituents and core structures.
- Methods of preparation: Synthesis pathways for the compounds, providing details on intermediates and reaction conditions.
- Therapeutic applications: Use of the compounds for treating conditions linked to kinase activity, such as cancers, inflammatory diseases, and other proliferative disorders.
Key Claims Breakdown
| Claim Type |
Number of Claims |
Summary |
| Composition of matter |
30 |
Defines the chemical structures with detailed substituent variations, including R groups and heterocycles. |
| Method of synthesis |
12 |
Describes patented synthetic routes, emphasizing efficiency and stereoselectivity. |
| Treatment methods |
18 |
Claims their use in treating specific diseases via administration of the compounds, covering dosages and formulations. |
Chemical Scope
The chemical scope focuses on:
- Heterocyclic cores such as pyridine, pyrimidine, and pyrimidinone.
- Substituents attached to the core rings that influence kinase selectivity.
- Variations that optimize pharmacokinetics and reduce off-target effects.
Limitations and Exclusivity
Claims are narrowly defined to include compounds with specific substitutions, reducing overlap with prior art but limiting breadth. The synthesis claims do not extend to generic methods outside the described processes, providing a secure platform for potential follow-on innovations but restricting broader chemical claims.
Patent Landscape
Patent Family and Priority
The patent is part of a family that includes filings in Europe (EP 2,610,076) and other jurisdictions, filed between 2012 and 2013, claiming priority to a provisional application filed in June 2012.
Related Patents and Competitors
Key related patents include:
- US Patent 9,127,166: Covering similar kinase inhibitor compounds with broader scope but different structural features.
- US Patent 9,497,183: Focusing on related synthesis methods for heterocyclic compounds.
Major competitors actively patenting in the kinase space include:
- Novartis
- Pfizer
- AstraZeneca
- Bristol-Myers Squibb
These companies hold multiple patents covering compounds, targets, and therapeutic methods similar to those in 8,951,969.
Patent Term and Expiry
- The patent has a term expiring in February 2033, considering patent term adjustments.
- It remains enforceable but faces near-term challenges from generic filings once exclusivity lapses.
Litigation and Patent Challenges
No public litigation records directly involve 8,951,969. However, the kinase inhibitor patent landscape is crowded, with ongoing patent interference proceedings and patent validity challenges, especially in Europe and the US post-AIA.
Strategic Implications
- The narrow scope limits free-use for generic development but provides strong protection against direct competitors.
- The patent’s coverage of synthesis methods complicates attempts to design around it.
- Its expiration date in 2033 keeps the compound class protected during promising drug development phases.
Key Takeaways
- US 8,951,969 protects a specific chemical class of kinase inhibitors with defined structural features and synthesis methods.
- Its claims are narrowly tailored to particular substitutions, offering targeted but limited exclusivity.
- The patent landscape is highly active, with competitors filing related patents covering similar compounds and applications.
- Its expiry in 2033 allows for potential generics or biosimilar activity afterward.
FAQs
Q1: What is the primary therapeutic focus of US Patent 8,951,969?
A1: The patent primarily addresses kinase inhibitors useful in treating cancers and inflammatory diseases.
Q2: How broad are the patent claims?
A2: Claims are narrow, covering specific chemical structures and synthesis methods, limiting broader generic use.
Q3: What is the expiration date of the patent?
A3: The patent is set to expire in February 2033, accounting for patent term adjustments.
Q4: Are there related patents with overlapping claims?
A4: Yes, patents such as US 9,127,166 and US 9,497,183 cover similar compounds and methods but with different structural features.
Q5: How does this patent impact competitors in the kinase inhibitor space?
A5: It provides protection against direct copies but does not block all similar compounds, especially those outside its narrow claims.
References
[1] U.S. Patent and Trademark Office. (2015). Patent No. 8,951,969.
[2] European Patent Office. (2014). Patent application EP 2,610,076.
[3] Drug Patent landscapes: kinase inhibitor patent publications (2012–2022). PubChem, PubMed.
